Transcutaneous tumor vaccination combined with anti-programmed death-1 monoclonal antibody treatment produces a synergistic antitumor effect
Source abstract
Abstract
Transcutaneous immunization (TCI) has the advantages of safety, high efficiency, non-invasiveness and convenient use. The key for a TCI system is transdermal targeted delivery of antigen to dendritic cells (DCs), the most powerful antigen presenting cells. DCs also play an important role in tumor immunotherapy, which provides a huge imagination for the application of TCI to tumor treatment. In this study, a transcutaneous tumor vaccine (TTV) delivery system was developed using the electrospun silk fibroin (SF) and polyvinyl alcohol (PVA) composite nanofibrous patch loaded with mannosylated polyethyleneimine (PEIman)-modified ethosome (Eth) (termed Eth-PEIman). Eth-PEIman showed a good performance in targeting DCs, and the carriers loaded with antigen (encapsulated in Eths) and adjuvant (absorbed in PEIman) were observed effectively induce DCs maturation in vitro. With the tyrosinase-related protein-2 (TRP2) peptide as antigen and oligodeoxynucleotides containing unmethylated CpG motifs as adjuvant, the TTV-loaded patches (TTVP) significantly inhibited the growth of melanoma in a syngeneic mouse model for melanoma by subcutaneous injection of B16F10 cell lines. Moreover, the combined application of the TTVP and anti-programmed death-1 monoclonal antibody (aPD-1) produced a synergistic antitumor effect, which could be related to the infiltration of more CD4+ and CD8+ T cells in the tumor tissues. The application of TTVP also increased the expression of IL-12, which may be part of the mechanism of synergistic antitumor effect between the TTVP and aPD-1. These results suggest that the combination of the TTVP and immune checkpoint blockers could be an effective strategy for tumor treatment. STATEMENT OF SIGNIFICANCE: Transcutaneous immunization has the advantages of safety, high efficiency, non-invasiveness and convenient use. In this study, a novel transcutaneous tumor vaccine patch (TTVP) was developed using tumor antigens-loaded ethosomes that can target dendritic cells percutaneously. Our data demonstrated that the TTVP can significantly inhibit tumor growth. Furthermore, the combination of TTVP and aPD-1 produced a synergistic anti-melanoma effect. Considering its convenience and non-invasiveness, this TTVP system could find good application prospects in immunotherapy. The combination of TTVP and aPD-1 could be a useful strategy for the prevention and treatment of tumors.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · CAR-T cell therapy research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (66)
Show source-provided references
1. Decisions about dendritic cells: past, present, and future10.1146/annurev-immunol-100311-102839 ↗
2. Interleukin-6 induced "acute" phenotypic microenvironment promotes Th1 anti-tumor immunity in cryo-thermal therapy revealed by shotgun and parallel reaction monitoring proteomics10.7150/thno.14394 ↗
3. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery10.1038/nm0402-415 ↗
4. Transcutaneous immunization: an emerging route of immunization and potent immunostimulation strategy10.1615/CritRevTherDrugCarrierSyst.v18.i5.30 ↗
5. Review of transcutaneous and intradermal vaccination10.4161/hv.7.8.16274 ↗
6. Overcoming or circumventing the stratum corneum barrier for efficient transcutaneous immunization10.1016/j.drudis.2017.09.017 ↗
7. Nanovesicular carriers as alternative drug delivery systems: ethosomes in focus10.1517/17425247.2013.860130 ↗
8. In vitro assessment of pharmaceutical potential of ethosomes entrapped with terbinafine hydrochloride10.1016/j.jare.2016.03.003 ↗
9. CD44 Assists the topical anti-psoriatic efficacy of curcumin-loaded hyaluronan-modified ethosomes: a new strategy for clustering drug in inflammatory skin10.7150/thno.29715 ↗
10. Design, characterization and comparison of transdermal delivery of colchicine via borneol-chemically-modified and borneol-physically-modified ethosome10.1080/10717544.2018.1559258 ↗
11. Enhanced transdermal bioavailability of testosterone propionate via surfactant-modified ethosomes10.2147/IJN.S46748 ↗
12. Polyethylenimine and sodium cholate-modified ethosomes complex as multidrug carrier for the treatment of melanoma through transdermal delivery10.2217/nnm-2018-0398 ↗
13. Galactosylated chitosan-modified ethosomes combined with silk fibroin nanofibers is useful in transcutaneous immunization10.1016/j.jconrel.2020.07.047 ↗
14. Dressed for success’ C-type lectin receptors for the delivery of glyco-vaccines to dendritic cells10.1016/j.coi.2010.11.011 ↗
15. Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formuLations following intravenous administration in mice10.1016/j.bbrc.2004.03.141 ↗
16. Comparative binding and uptake of liposomes decorated with mannose oligosaccharides by cells expressing the mannose receptor or dc-sign10.1016/j.carres.2019.107877 ↗
17. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation10.1084/jem.184.2.747 ↗
18. CPG loaded MoS(2) nanosheets as multifunctional agents for photothermal enhanced cancer immunotherapy10.1039/C7NR01460K ↗
19. Clinical evaluation of CPG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer10.1016/j.vaccine.2014.06.065 ↗
20. Nanoscale zeolitic imidazolate framework-8 as efficient vehicles for enhanced delivery of CPG oligodeoxynucleotides10.1021/acsami.7b09583 ↗
21. Inflammation-triggered cancer immunotherapy by programmed delivery of CPG and anti-PD1 antibody10.1002/adma.201506312 ↗
22. Therapeutic potential of toll-like receptor 9 activation10.1038/nrd2059 ↗
23. DEC-205 is a cell surface receptor for CPG oligonucleotides10.1073/pnas.1208796109 ↗
24. Nanodelivery systems for enhancing the immunostimulatory effect of cpg oligodeoxynucleotides10.1016/j.msec.2016.03.045 ↗
25. Investigation of dendritic mesoporous silica nanoparticles for cytosine-phosphate-guanosine oligodeoxynucleotide delivery10.1166/mex.2016.1288 ↗
26. Current status of polymeric gene delivery systems10.1016/j.addr.2006.03.007 ↗
27. Polyethylenimine: a versatile, multifunctional non-viral vector for nucleic acid delivery10.1016/j.msec.2016.07.066 ↗
28. A biodegradable low molecular weight polyethylenimine derivative as low toxicity and efficient gene vector10.1021/bc800428y ↗
29. Polyethylenimine-mediated CPG oligodeoxynucleotide delivery stimulates bifurcated cytokine induction10.1021/acsbiomaterials.8b00049 ↗
30. Synthesis of mannosylated polyethylenimine and its potential application as cell-targeting non-viral vector for gene therapy10.3390/polym6102573 ↗
31. A mannosylated cell-penetrating peptide-graft-polyethylenimine as a gene delivery vector10.1016/j.biomaterials.2014.01.065 ↗
32. A mannosylated pei-cpp hybrid for trail gene targeting delivery for colorectal cancer therapy10.1039/C7PY00882A ↗
33. Benzoyl peroxide microsphere formulations: what is the science supporting microsphere vehicle technology and clinical use?
34. Fabrication and properties of superhydrophobic waterborne polyurethane composites with micro-rough surface structure using electrostatic spraying
35. Nanofiber technology: designing the next generation of tissue engineering scaffolds10.1016/j.addr.2007.04.022 ↗
36. Green electrospun Manuka honey/silk fibroin fibrous matrices as potential wound dressing10.1016/j.matdes.2017.01.023 ↗
37. Silk fibroin-Pellethane® cardiovascular patches: effect of silk fibroin concentration on vascular remodeling in rat model10.1007/s10856-017-5999-z ↗
38. Estradiol-loaded poly(ε-caprolactone)/silk fibroin electrospun microfibers decrease osteoclast activity and retain osteoblast function10.1021/acsami.8b01855 ↗
39. 3-D mineralized silk fibroin/polycaprolactone composite scaffold modified with polyglutamate conjugated with BMP-2 peptide for bone tissue engineering10.1016/j.colsurfb.2017.12.043 ↗
40. Starch nanoparticle as a vitamin E-TPGS carrier loaded in silk fibroin-poly(vinyl alcohol)-Aloe vera nanofibrous dressing10.1016/j.colsurfb.2018.03.004 ↗
41. Nanofibrous nonmulberry silk/PVA scaffold for osteoinduction and osseointegration10.1002/bip.22594 ↗
42. Bactericidal and antifouling electrospun PVA nanofibers modified with a quaternary ammonium salt and zwitterionic sulfopropylbetaine10.1016/j.msec.2020.110855 ↗
43. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer10.1056/NEJMoa1200690 ↗
44. Advances in targeting cell surface signalling molecules for immune modulation. Nature reviews10.1038/nrd3877 ↗
45. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study10.1186/s40425-019-0659-0 ↗
46. Understanding genetic determinants of resistance to immune checkpoint blockers10.1016/j.semcancer.2019.12.020 ↗
47. Sting agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade10.1126/scitranslmed.aaa4306 ↗
48. Targeting TMEM176B enhances antitumor immunity and augments the efficacy of immune checkpoint blockers by unleashing inflammasome activation10.1016/j.ccell.2019.04.003 ↗
49. Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade
50. Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment10.1016/j.bbcan.2018.12.002 ↗
51. Strategies of combination drug delivery for immune checkpoint blockades10.1002/adhm.201801099 ↗
52. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving thecytokines IFN-γ and IL-1210.1016/j.immuni.2018.09.024 ↗
53. Dendritic cell activation by an E. coli-derived monophosphoryl lipid A enhances the efficacy of PD-1 blockade10.1016/j.canlet.2019.12.012 ↗
54. Functionalized selenium nanoparticles for targeted siRNA delivery silence Derlin1 and promote antitumor efficacy against cervical cancer10.1080/10717544.2019.1667452 ↗
55. Folate-modified chitosan nanoparticles containing the IP-10 gene enhance melanoma-specific cytotoxic CD8(+)CD28(+) T lymphocyte responses10.7150/thno.14527 ↗
56. Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma10.1016/j.jconrel.2018.01.004 ↗
57. The enhanced antitumor-specific immune response with mannose- and CPG-ODN-coated liposomes delivering Trp2 peptide10.7150/thno.22056 ↗
58. Trp2 peptide vaccine adjuvanted with (R)-DOTAP inhibits tumor growth in an advanced melanoma model10.1021/mp200350n ↗
59. Cationic micelle delivery of Trp2 peptide for efficient lymphatic draining and enhanced cytotoxic T-lymphocyte responses10.1016/j.jconrel.2014.12.024 ↗
60. Nanoparticles and nanofibers for topical drug delivery10.1016/j.jconrel.2015.10.049 ↗
61. Influence of PVP/VA copolymer composition on drug-polymer solubility10.1016/j.ejps.2016.01.026 ↗
62. In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model10.1016/j.jconrel.2014.11.033 ↗
63. Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment10.1016/j.jconrel.2016.11.013 ↗
64. A melanin-mediated cancer immunotherapy patch10.1126/sciimmunol.aan5692 ↗
65. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape10.1007/s00262-004-0517-9 ↗
66. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival10.1038/nm.2883 ↗